Farzana Pashankar

Yale New Haven Hospital — United States

Medicine · Health Sciences

26h-index2.3kcitations124works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Testicular diseases and treatments(53), Neuroblastoma Research and Treatments(33), Hemoglobinopathies and Related Disorders(26), Ovarian cancer diagnosis and treatment(22), Glioma Diagnosis and Treatment(16)

Publications124 total

Factors Associated With Rare Pediatric Cancer Trial Enrollment: A Report From the Children's Oncology Group Rare Tumors Committee
Pediatric Blood & Cancer·2025Open Access
Influenza vaccine coverage, effectiveness, and disease burden among pediatric sickle cell patients in Connecticut from 2021-2024: A test-negative case-control study
Blood·2025Open Access
Building Education and Training Success (BEATS): A Conference to Raise Awareness and Interest in the Field of Pediatric Hematology/Oncology (PHO) for Residents and Medical Students
Academic Pediatrics·2025
Outcome of Children With Intermediate‐Risk Extracranial Malignant Germ Cell Tumors by Response Status at the End of Induction Chemotherapy: A Report From the Children's Oncology Group
Pediatric Blood & Cancer·2025
One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma
Clinical Cancer Research·2025· 1 cited
Phase 1/2 study of zilovertamab vedotin in pediatric and young adult hematologic malignancies or solid tumors (LIGHTBEAM-U01A).
Journal of Clinical Oncology·2025
Abstract CT119: Zilovertamab vedotin in pediatric and young adult hematologic malignancies or solid tumors: Phase 1/2 LIGHTBEAM-U01A study
Cancer Research·2025
Pediatric Hematology Oncology Building Education and Training Success (PHO BEATS): A Conference to Raise Awareness and Interest for Residents and Medical Students
Pediatric Blood & Cancer·2025Open Access
Standard‐Dose Versus High‐Dose Cisplatin for Intermediate/Poor‐Risk Extracranial Malignant Germ Cell Tumors: Re‐Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification
Pediatric Blood & Cancer·2025· 1 citedOpen Access
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Journal of Clinical Oncology·2025
Comparing Clinicopathologic Features and Outcomes Between Young Children, Adolescents, and Adults with Rhabdomyosarcoma at a Single Institution
2025Open Access
Genome-Wide Association Study of Chronic Pain in Sickle Cell Disease
Blood·2024
Genome-Wide Association Study Identifies Novel Genetic Variants Associated with Avascular Necrosis in Sickle Cell Disease
Blood·2024Open Access
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network·2024· 34 cited
Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review
International Journal of Gynecological Cancer·2024· 3 cited
Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective
EClinicalMedicine·2024· 16 citedOpen Access
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Journal of Clinical Oncology·2024
Normal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain
Journal of Pediatric Hematology/Oncology·2024
Standardized Clinical Pathways Improve Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department
Blood·2023· 1 citedOpen Access
Normal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain
2023
page 1 of 7Next →

Frequent Co-authors

A. Lindsay Frazier(22), Mark Krailo(20), Carlos Rodríguez‐Galindo(17), Deborah F. Billmire(17), Thomas A. Olson(15), Furqan Shaikh(15), James F. Amatruda(12), Sara Stoneham(10), Matthew J. Murray(9), James C. Nicholson(8), Caihong Xia(8), Marcio H. Malogolowkin(7), Juliet Hale(6), Dan Stark(6), Ha Dang(5), Alberto S. Pappo(5), Bryan J. Dicken(5), John Hicks(4), Frederick J. Rescorla(4), David M. Gershenson(4)